Mutual of America Capital Management LLC Sells 16,738 Shares of Insmed, Inc. $INSM

Mutual of America Capital Management LLC lowered its stake in Insmed, Inc. (NASDAQ:INSM) by 19.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 69,754 shares of the biopharmaceutical company’s stock after selling 16,738 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Insmed were worth $10,045,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Chung Wu Investment Group LLC purchased a new stake in shares of Insmed in the second quarter worth $173,000. EULAV Asset Management bought a new position in Insmed in the 3rd quarter worth $12,961,000. Resolute Capital Asset Partners LLC bought a new position in Insmed in the 2nd quarter worth $2,748,000. Nisa Investment Advisors LLC raised its holdings in Insmed by 374.6% during the third quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock valued at $1,507,000 after acquiring an additional 8,261 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Insmed in the second quarter valued at about $5,578,000.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on INSM. Rothschild Redb upgraded Insmed to a “strong-buy” rating in a research report on Thursday, December 4th. Jefferies Financial Group set a $269.00 price objective on shares of Insmed in a report on Wednesday, December 10th. Redburn Partners set a $263.00 target price on shares of Insmed in a report on Thursday, December 4th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a research note on Friday. Finally, UBS Group decreased their price target on shares of Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, January 6th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insmed has an average rating of “Buy” and an average target price of $204.68.

Insmed Price Performance

Insmed stock opened at $159.72 on Tuesday. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The firm’s fifty day moving average is $183.65 and its 200 day moving average is $157.39. The company has a market cap of $34.06 billion, a price-to-earnings ratio of -25.80 and a beta of 1.08.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same quarter last year, the firm earned ($1.27) earnings per share. The business’s quarterly revenue was up 52.4% on a year-over-year basis. Sell-side analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Roger Adsett sold 2,059 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total transaction of $358,616.03. Following the sale, the chief operating officer owned 107,601 shares in the company, valued at approximately $18,740,866.17. This represents a 1.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $158.93, for a total value of $1,700,392.07. Following the completion of the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at approximately $48,774,186.63. This represents a 3.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 296,799 shares of company stock valued at $54,296,286. 3.00% of the stock is currently owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.